Plain-English translation of NCT07192068 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , which is designed to attack cancer cells that have a specific change in their HER2 gene. The medication has already been approved in Europe for bile duct cancer and has shown promise in early studies for several other cancer types. This study will evaluate whether the medication can reduce tumor size in patients with five specific types of advanced cancer.
Many different cancers contain a faulty HER2 gene, but the new treatment hasn't been thoroughly tested in most of these cancer types yet. This trial exists to see if this medication could become a new treatment option for patients whose cancers have stopped responding to standard therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication by IV infusion once every three weeks at a hospital or clinic. You will need to visit regularly—roughly every 3 weeks for treatment and every 6 weeks for scans during the first 18 months, then every 12 weeks after that—so doctors can check for side effects and monitor whether your tumor is shrinking. The medication is weight-based, so your dose depends on your body weight. Treatment continues as long as the medication is helping and you're tolerating it well; if your cancer progresses or you experience severe side effects, your doctors may adjust your dose or stop treatment and continue monitoring you for 1 to 4 years depending on when you joined the study.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France